Profile data is unavailable for this security.
About the company
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cells’ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.
- Revenue in USD (TTM)0.00
- Net income in USD-7.95m
- Incorporated2011
- Employees5.00
- LocationPhio Pharmaceuticals Corp411 Swedeland Road, Suite 23-1080KING OF PRUSSIA 19406United StatesUSA
- Phone+1 (508) 767-3861
- Fax+1 (508) 767-3862
- Websitehttps://phiopharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemomab Therapeutics Ltd - ADR | 0.00 | -10.09m | 11.45m | 16.00 | -- | 1.02 | -- | -- | -5.87 | -5.87 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -60.63 | -- | -72.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Ainos Inc | 113.04k | -14.96m | 11.45m | 44.00 | -- | 0.7827 | -- | 101.31 | -4.29 | -4.29 | 0.0307 | 2.10 | 0.0042 | 0.12 | 3,768.00 | 2,569.09 | -55.34 | -38.46 | -60.63 | -55.22 | 82.62 | 35.93 | -13,231.35 | -1,122.70 | 2.67 | -19.92 | 0.5227 | -- | -83.02 | 12.06 | -7.93 | -- | 10.22 | -- |
| Longeveron Inc | 1.44m | -21.34m | 11.55m | 25.00 | -- | 1.14 | -- | 8.04 | -1.34 | -1.34 | 0.0909 | 0.4732 | 0.0632 | -- | 6.65 | 57,480.00 | -93.88 | -70.26 | -114.04 | -83.92 | 74.88 | 44.57 | -1,485.11 | -683.81 | -- | -- | 0.00 | -- | 237.38 | -15.76 | -10.86 | -- | 51.32 | -- |
| Check Cap Ltd | 0.00 | -13.62m | 11.88m | 85.00 | -- | 2.53 | -- | -- | -2.33 | -2.33 | 0.00 | 0.6432 | 0.00 | -- | -- | -- | -114.23 | -61.64 | -130.02 | -67.99 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.15 | -- | -- | -- |
| Soligenix Inc | 0.00 | -11.46m | 11.90m | 14.00 | -- | 1.53 | -- | -- | -3.66 | -3.66 | 0.00 | 0.7705 | 0.00 | -- | -- | 0.00 | -105.25 | -73.79 | -165.82 | -151.46 | -- | 22.19 | -- | -1,147.93 | -- | -- | 0.00 | -- | -85.78 | -51.89 | -34.62 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 11.96m | 13.00 | -- | 1.42 | -- | 757.48 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| Phio Pharmaceuticals Corp | 0.00 | -7.95m | 12.27m | 5.00 | -- | 0.6703 | -- | -- | -2.73 | -2.73 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -91.57 | -73.65 | -107.58 | -86.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 33.96 | -- | -57.49 | -- |
| Kairos Pharma Ltd | 0.00 | -5.06m | 12.61m | 1.00 | -- | 1.65 | -- | -- | -0.3045 | -0.3045 | 0.00 | 0.3681 | 0.00 | -- | -- | 0.00 | -77.46 | -- | -92.07 | -- | -- | -- | -- | -- | -- | -94.05 | 0.00 | -- | -- | -- | -43.65 | -- | -- | -- |
| GT Biopharma Inc | 0.00 | -9.33m | 12.74m | 1.00 | -- | 0.9646 | -- | -- | -3.38 | -3.38 | 0.00 | 0.4957 | 0.00 | -- | -- | 0.00 | -164.22 | -180.24 | -356.99 | -8,448.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -73.25 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 12.76m | -- | -- | 0.8929 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Hookipa Pharma Inc | 9.35m | -73.31m | 12.95m | 82.00 | -- | 0.3719 | -- | 1.38 | -5.85 | -5.85 | 0.7457 | 2.82 | 0.0903 | -- | 1.74 | 114,036.60 | -70.79 | -40.82 | -91.08 | -50.56 | -- | -- | -784.01 | -266.20 | -- | -- | 0.00 | -- | 118.32 | 29.77 | 46.67 | -- | -37.28 | -- |
| Traws Pharma Inc | 2.85m | 93.35m | 13.18m | 7.00 | 0.0584 | 2.59 | -- | 4.63 | 28.24 | 28.24 | 0.4566 | 0.6373 | 0.2662 | -- | 1.38 | 406,571.40 | -124.51 | -151.85 | -517.46 | -207.35 | -- | -- | -467.64 | -21,652.42 | -- | -- | 0.00 | -- | 0.00 | -36.47 | -188.55 | -- | -- | -- |
| NewcelX AG | 0.00 | -6.21m | 13.22m | 1.00 | -- | 0.4272 | -- | -- | -20.39 | -20.39 | 0.00 | 6.94 | 0.00 | -- | -- | 0.00 | -78.31 | -232.34 | -- | -- | -- | -- | -- | -- | -- | -53.01 | 0.00 | -- | -- | -- | 66.67 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Geode Capital Management LLCas of 31 Dec 2025 | 92.64k | 0.86% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 49.46k | 0.46% |
| Cetera Investment Advisers LLCas of 31 Dec 2025 | 42.50k | 0.40% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 38.17k | 0.36% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 23.76k | 0.22% |
| DRW Securities LLCas of 31 Dec 2025 | 22.64k | 0.21% |
| G1 Execution Services LLCas of 31 Dec 2025 | 20.09k | 0.19% |
| Two Sigma Investments LPas of 31 Dec 2025 | 14.49k | 0.14% |
| StoneX Group, Inc. (Investment Management)as of 31 Dec 2025 | 11.83k | 0.11% |
| Robertson Stephens Wealth Management LLC (Invt Mgmt)as of 31 Dec 2025 | 10.80k | 0.10% |
